Stay updated with breaking news from Ingmar Hoerr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A coronavirus vaccine being developed by Germany's CureVac is facing delays as its late-stage trial is slowed by the wait for enough participants to catch Covid, officials said Friday.
Curevac investor sees bright future for German vaccine maker Friedrich von Bohlen believes equity and incentives can intensify medical innovation about 6 hours ago Two centuries ago, Friedrich Krupp, a struggling German inventor and would-be industrialist, was not yet 40 when he died in debt, leaving behind a wife, four children and an unrealised dream. It fell to his son Alfred Krupp to harvest the seeds he had planted and lead a revolution that saw imperial Germany steal Victorian Britain’s steel crown with the Krupp family on the throne. Two centuries on, what remains of the Krupp st...
DER SPIEGEL Suche öffnen BioNTech, CureVac and Co. Patent Suspensions Threaten Germany's Booming Biotech Industry With their next-generation mRNA vaccines, the German companies BioNTech and CureVac are at the forefront of pharmaceutical innovation. But U.S. President Joe Biden's plan to suspend patent protections is threatening that position. Şahin: Their company is also working on vaccines against the flu and cancer. Foto: Ramon Haindl Usually, hindsight is necessary to identify the moment a new technology is born. When Steve Jobs presented the first iPhone in January 2007, many experts...
/cloudfront-ap-southeast-2.images.arcpublishing.com/nzme/7YHBLCJPR2VZWVUA5PGAP4M35U.jpg)
Covid 19 coronavirus: This new vaccine could bring hope to the unvaccinated world 5 May, 2021 08:46 PM 10 minutes to read Curevac's headquarters in Tuebingen, Germany. Photo / AP New York Times By: Carl Zimmer The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month. In early 2020, dozens of scientific teams scrambled to make a vaccine for Covid-19. Some chose tried-and-true techniques, such as making vaccines from killed viruses. But a handful of companies bet on a riskier method, one that had never ...
A year ago, Gaithersburg, Maryland-based Novavax Inc. (NASDAQ:NVAX) was a struggling biotech company; fast forward to the present and NVAX is 2,500% more valuable than it was 12 months ago, thanks mainly to its very promising Covid-19 vaccine candidate, NVX-CoV2373. A few days ago, Novavax announced that clinical tests had shown that its coronavirus vaccine was 96.4% effective against mild, moderate and severe cases of Covid-19 caused by the original strain and also 48.6% effective in a midstage test in South Africa where mutated strains are dominant. That makes NVX-CoV2373 the most successf...